Investment Analysts’ Weekly Ratings Updates for Sage Therapeutics (SAGE)

A number of firms have modified their ratings and price targets on shares of Sage Therapeutics (NASDAQ: SAGE) recently:

• 2/12/2025 – Sage Therapeutics had its price target lowered by analysts at Scotiabank from $14.00 to $12.00. They now have a “sector outperform” rating on the stock.
• 2/12/2025 – Sage Therapeutics had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
• 2/12/2025 – Sage Therapeutics had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock, down previously from $14.00.
• 2/12/2025 – Sage Therapeutics had its price target lowered by analysts at Canaccord Genuity Group Inc. from $9.00 to $8.00. They now have a “hold” rating on the stock.
• 2/12/2025 – Sage Therapeutics had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 1/2/2025 – Sage Therapeutics had its price target lowered by analysts at Piper Sandler from $26.00 to $9.00. They now have an “overweight” rating on the stock.

Sage Therapeutics Price Performance

NASDAQ:SAGE traded up $0.16 during mid-day trading on Friday, hitting $7.31. The company’s stock had a trading volume of 1,926,954 shares, compared to its average volume of 2,359,868. The business’s fifty day moving average is $6.52 and its two-hundred day moving average is $6.82. The stock has a market cap of $449.42 million, a price-to-earnings ratio of -1.11 and a beta of 0.94. Sage Therapeutics, Inc. has a 1 year low of $4.62 and a 1 year high of $23.22.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. Analysts anticipate that Sage Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Sage Therapeutics

Several institutional investors have recently made changes to their positions in SAGE. State Street Corp grew its position in Sage Therapeutics by 18.2% during the third quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock valued at $21,127,000 after buying an additional 451,377 shares during the period. RTW Investments LP boosted its stake in shares of Sage Therapeutics by 2.0% during the 3rd quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock worth $40,372,000 after acquiring an additional 111,123 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Sage Therapeutics by 10.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company’s stock valued at $3,265,000 after acquiring an additional 43,617 shares during the period. Geode Capital Management LLC increased its stake in shares of Sage Therapeutics by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock valued at $8,975,000 after purchasing an additional 3,757 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Sage Therapeutics in the 3rd quarter worth about $473,000. 99.22% of the stock is owned by hedge funds and other institutional investors.

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.